- Home
- EGY vs LYEL Comparison
EGY vs LYEL Comparison
Compare EGY & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- LYEL
- Stock Information
- Founded
- EGY 1985
- LYEL 2018
- Country
- EGY United States
- LYEL United States
- Employees
- EGY N/A
- LYEL N/A
- Industry
- EGY Oil & Gas Production
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- EGY Energy
- LYEL Health Care
- Exchange
- EGY Nasdaq
- LYEL Nasdaq
- Market Cap
- EGY 412.9M
- LYEL 369.4M
- IPO Year
- EGY N/A
- LYEL 2021
- Fundamental
- Price
- EGY $3.74
- LYEL $16.95
- Analyst Decision
- EGY
- LYEL Buy
- Analyst Count
- EGY 0
- LYEL 2
- Target Price
- EGY N/A
- LYEL $15.00
- AVG Volume (30 Days)
- EGY 701.9K
- LYEL 25.6K
- Earning Date
- EGY 11-10-2025
- LYEL 11-12-2025
- Dividend Yield
- EGY 6.68%
- LYEL N/A
- EPS Growth
- EGY N/A
- LYEL N/A
- EPS
- EGY 0.27
- LYEL N/A
- Revenue
- EGY $389,951,000.00
- LYEL $41,000.00
- Revenue This Year
- EGY N/A
- LYEL N/A
- Revenue Next Year
- EGY $23.20
- LYEL N/A
- P/E Ratio
- EGY $13.86
- LYEL N/A
- Revenue Growth
- EGY N/A
- LYEL N/A
- 52 Week Low
- EGY $3.00
- LYEL $7.65
- 52 Week High
- EGY $5.47
- LYEL $23.20
- Technical
- Relative Strength Index (RSI)
- EGY 44.23
- LYEL 59.12
- Support Level
- EGY $3.66
- LYEL $16.77
- Resistance Level
- EGY $3.95
- LYEL $18.80
- Average True Range (ATR)
- EGY 0.12
- LYEL 1.34
- MACD
- EGY -0.01
- LYEL -0.03
- Stochastic Oscillator
- EGY 25.00
- LYEL 74.92
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea, and Cote d'Ivoire. The company generates maximum revenue from the Gabon segment.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.